CDC40抗体;CDC40 Antibody—艾普蒂

+ +

•  

   

     Western blot analysis of CDC40 expression in (1) HeLa cell lysate; (2) K562 cell lysate.    

  
  

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

The CDC40 antibody targets the Cell Division Cycle 40 protein (CDC40), a conserved splicing factor critical for pre-mRNA processing and cell cycle progression. CDC40. also known as PRP17. is a core component of the spliceosome, facilitating the removal of introns during RNA splicing. It plays a key role in maintaining genomic stability by ensuring accurate splicing of transcripts involved in DNA repair, mitosis, and checkpoint control. Dysregulation of CDC40 has been linked to cancers, developmental disorders, and cell cycle defects, highlighting its importance in cellular homeostasis.

Antibodies against CDC40 are essential tools for studying its expression, localization, and molecular interactions. They enable detection via techniques like Western blotting, immunofluorescence, and immunoprecipitation, aiding in investigations of spliceosome dynamics and cell cycle regulation. Researchers use these antibodies to explore CDC40's role in diseases, particularly its overexpression in malignancies such as colorectal and hepatocellular carcinomas, where it correlates with poor prognosis.

Commercial CDC40 antibodies are typically raised in rabbits or mice, with validation across multiple applications. Their specificity and reliability support mechanistic studies, including how CDC40 mutations or aberrant splicing contribute to pathological conditions. These tools continue to advance understanding of post-transcriptional gene regulation and therapeutic targeting of spliceosome-related disorders.